Business Context and Reporting Period
The filing is Histogenics Corporation’s unaudited Form 10-Q for the three months ended March 31, 2018. The supplied metadata identifies Ocugen, Inc., but the filing itself names Histogenics Corporation; investors should verify the issuer identity.
Histogenics is a clinical-stage restorative cell therapy company developing NeoCart, an investigational treatment for knee cartilage damage. NeoCart enrollment was complete in a 249-patient Phase 3 U.S. trial, with top-line one-year superiority data and a potential FDA Biologics License Application submission expected in the third quarter of 2018, subject to successful results.
Financial Performance and Position
| Metric | Q1 2018 | Q1 2017 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $3.3 million | $4.5 million | Down 27% |
| General and administrative expense | $2.8 million | $2.3 million | Up 21% |
| Loss from operations | $6.1 million | $6.8 million | Improved $0.7 million |
| Net loss | $14.8 million | $7.1 million | Worsened $7.8 million |
| Net loss attributable to common stockholders | $14.4 million | $5.8 million | Worsened $8.5 million |
| Basic and diluted loss per share | $0.52 loss | $0.27 loss | Worsened $0.25 |
| Net cash from operating activities | $3.3 million | $(7.3) million | Improved $10.6 million |
The Q1 2018 net loss included an $8.8 million non-cash expense from the increase in the fair value of the warrant liability, compared with $0.3 million in Q1 2017. Excluding this unusual fair-value adjustment, the operating cost structure was the primary driver of losses.
- Cash and cash equivalents were $15.5 million at March 31, 2018, compared with $7.1 million at December 31, 2017.
- Cash, cash equivalents and restricted cash totaled $15.6 million at March 31, 2018. No marketable securities remained at quarter-end.
- Total assets were $21.3 million and total liabilities were $41.4 million, resulting in stockholders’ deficit of $20.1 million.
- The warrant liability was $23.4 million, compared with $14.7 million at December 31, 2017.
- Equipment loan debt was $45,000, all classified as current, and was scheduled to mature on May 31, 2018.
- Accumulated deficit was $223.0 million at March 31, 2018.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined by $1.2 million, primarily because of lower clinical trial, consulting, salary-related, depreciation and patient recruitment costs.
- General and administrative expense increased by approximately $0.5 million because of higher salary-related, consulting, public relations and facility costs.
- Operating cash flow turned positive primarily because of the $10.0 million upfront payment received from MEDINET. The payment was recorded as deferred revenue rather than recognized revenue.
- In January 2018, the company issued 2.7 million common shares and received net proceeds of $5.7 million.
- In March 2018, the company established an at-the-market facility permitting sales of up to $10.0 million of common stock; no shares were sold under the facility during the quarter.
- Common shares outstanding increased to 28.7 million at March 31, 2018 from 24.6 million at December 31, 2017, primarily reflecting the January offering.
- Property and equipment, net increased to $4.4 million from $2.7 million, including $1.3 million of capital expenditures during the quarter.
Outlook, Commentary, Risks and Unusual Items
The MEDINET agreement grants exclusive Japanese commercialization rights and provided a $10.0 million non-refundable upfront payment. The amount was wholly deferred because the related performance obligation had not yet been performed. Histogenics expected to begin clinical manufacturing services for MEDINET in the fourth quarter of 2018 and recognize the upfront payment over an estimated one-year clinical trial enrollment period.
Management expected research and development expenses to decline over the following three quarters as the NeoCart Phase 3 trial was completed, while general and administrative expenses were expected to increase in preparation for potential commercialization.
The company stated that existing cash, cash equivalents and marketable securities were expected to fund operations only into the fourth quarter of 2018. The filing therefore disclosed substantial doubt about the company’s ability to continue as a going concern. Additional debt, equity or strategic financing was expected to be necessary, but availability and terms were uncertain.
- NeoCart remained subject to successful Phase 3 results, FDA review, manufacturing comparability requirements and approval; no product candidate had received regulatory approval.
- Manufacturing technology transfers, FDA inspections, raw-material comparability, production capacity and reliance on sole- or limited-source suppliers could delay development or commercialization.
- Future financing could dilute existing stockholders, increase fixed obligations or impose restrictive covenants.
- The warrant liability was classified as a Level 3 fair-value liability and was sensitive to the company’s stock price and other valuation assumptions.
- The company had contingent license and collaboration obligations, including potential milestone and royalty payments to licensors and Intrexon.
- There were no material pending legal proceedings identified by management, and no off-balance-sheet arrangements were reported.
- Management concluded that disclosure controls and procedures were effective as of March 31, 2018.
Facts Investors Should Verify
- Confirm whether the filing belongs to Histogenics Corporation or Ocugen, Inc., because the supplied company metadata conflicts with the filing issuer.
- Verify the timing and results of the NeoCart Phase 3 data readout and whether an FDA BLA was submitted.
- Assess the company’s ability to raise capital before the projected fourth-quarter 2018 cash runway expires.
- Separate cash generated by the MEDINET upfront payment from recurring operating revenue; no revenue was recognized in Q1 2018.
- Monitor the $23.4 million warrant liability and its potential effect on reported earnings and stockholders’ deficit.
- Review dilution risk from the $10.0 million ATM facility, outstanding warrants for approximately 13.6 million shares, preferred stock convertible into approximately 0.6 million shares, and equity compensation awards.
- Confirm repayment of the equipment loan and compliance with related covenants.